Clik here to view.
Novartis’ Ultibro Breezhaler tops corticosteroid for COPD in head-to-head study
Novartis (NYSE:NVS) said today that a new analysis of its head-to-head Flame trial showed that inhaled corticosteroids may not be necessary in some chronic obstructive pulmonary disease patients with...
View ArticleClik here to view.
Trump proposes deep cuts to Medicaid, NIH funding
President Donald Trump’s proposed budget would slash Medicaid funding and cut support for major biomedical research programs at the National Institutes of Health and the Centers for Disease Control...
View ArticleClik here to view.
UK watchdog accuses Merck of restricting biosimilar competition
Britain’s Competition and Markets Authority accused Merck‘s (NYSE:MRK) European unit, Merck Sharp & Dohme, of conducting an unfair discount scheme that it said was designed to restrict competition...
View ArticleClik here to view.
Anika onshores manufacturing capabilities with new Bedford facility
Anika Therapeutics (NSDQ:ANIK) opened a new global manufacturing facility today, on the same day that it celebrated the 25th anniversary of its Bedford, Mass.-based headquarters. Anika’s manufacturing...
View ArticleClik here to view.
Valeritas touts cost savings, real-world outcomes with V-Go insulin pump
In a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to...
View ArticleClik here to view.
ATS Roundup: Emulate models viral infection in “asthma-on-a-chip”
Emulate‘s small airway-lung chip could help researchers study viral-induced exacerbations of asthma, according to data presented this week at the American Thoracic Society’s annual meeting. The studies...
View ArticleClik here to view.
Medtronic launches study of In.Pact Admiral drug-coated balloon in end-stage...
Medtronic (NYSE:MDT) said today that the 1st patient was enrolled in a study of its In.Pact Admiral drug-coated balloon in patients with end-stage renal disease. The FDA approved the investigational...
View ArticleClik here to view.
FDA approves 1st cancer drug based on genetics, not tissue type
In a landmark decision, the FDA approved Merck‘s (NYSE:MRK) immunotherapy Keytruda yesterday as the 1st cancer treatment indicated for any solid tumor with a specific genetic feature, regardless of...
View ArticleClik here to view.
Liquidia touts Phase I data for sustained-release post-surgical pain reliever
Liquidia Technologies touted initial data from its LIQ865 Phase I trial, which evaluated its sustained-delivery formulation of bupivacaine for post-surgical pain relief. The trial was the 1st...
View ArticleClik here to view.
BioCorRx to meet with the FDA for injectable, sustained-release opioid...
BioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19. The Anaheim, Calif.-based company said it is slated...
View ArticleClik here to view.
Ultrasound-drug combo treats pulmonary embolism in less time with fewer drugs
When venous clots break off and travel through a patient’s circulatory system, they can become trapped in the lung and block blood flow. This strains the heart’s ability to pump blood through the lungs...
View ArticleClik here to view.
FDA chief: Changing generics regulations could reel in drug prices
Part of the FDA commissioner’s job is to oversee the federal regulatory watchdog as it evaluates pharmaceuticals for safety and efficacy. Most FDA chiefs have avoided the topic of drug prices, given...
View ArticleClik here to view.
Study: Radiation may boost immunotherapy in mesothelioma treatment
Doctors in Pennsylvania reported this week that combining immunotherapy drugs with radiotherapy could help to more efficiently treat malignant pleural mesothelioma. The analysis from the University of...
View ArticleClik here to view.
Colorectal cancer patients treated with SIR-spheres more likely to be...
Treatment with Sirtex Medical‘s (ASX:SRX) Y-90 resin microspheres and chemotherapy was associated with a statistically significant gain in potentially curative liver resectability, according to data...
View ArticleClik here to view.
SteadyMed raises another $5m from key shareholder
SteadyMed (NSDQ:STDY) said today that 1 of its largest institutional shareholders exercised warrants to purchase additional shares of the company that the investor got in conjunction with the 1st...
View ArticleClik here to view.
Anika launches late-stage supplemental Cingal study
Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination...
View ArticleClik here to view.
7 medtech stories we missed this week: May 26, 2017
[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks...
View ArticleClik here to view.
Potential Alcon sale worries Novartis investors
Novartis (NYSE:NVS) CEO Joe Jimenez’s consideration of the sale of the Alcon subsidiary has investors worried that the influx of cash – Alcon’s surgical devices and contact lens business could fetch as...
View ArticleClik here to view.
FDA deals setback to Sunovion for inhaled COPD therapy
The FDA issued a complete response letter to Sunovion Pharmaceuticals in regards to the new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The investigational...
View ArticleClik here to view.
X-Biotix to address antibiotic resistance with chemical scaffolds
X-Biotix Therapeutics launched today with technology from Harvard Medical School that the company said will aim to address the threat of antibiotic resistance. According to the multi-year collaboration...
View Article